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Systemic treatment of metastatic malignant melanoma
A. Benhammouda, E.C. Antoine, W. Daou, N. Mortier, G. Auclerc, D. Nizri, 
Cl. Soubrana, V. Bassot, M. Weil, D. Khavat. Salpêtrière Hospital, Paris, 
France
C hem otherapy: Systemic therapy for melanoma, both as adjuvant therapy 
and for treatment of disseminated (stage IV) disease, remains unsatisfac­
tory. Patients with high-risk or metastatic disease should be considered for 
enrollment in investigational studies. Few chemotherapeutic agents have 
demonstrated antitumor activity against metastatic melanoma. In a review 
of phase II trials, only 4 of 30 drugs that were tested demonstrated a 
response rate greater than 18% in melanoma patients. The best-studied 
single agents for treatment of melanoma are Dacarbazine (D) (20% RR), 
Fotemustine (F) (24% RR), Vindesine (V) (14% RR) and Cisplatin (P) (23%
R R ).
C om bination: The role of combination chemotherapy in treatment of 
advanced melanoma is not entirely clear. The most active combination 
regim ens (FDV) (32% RR) and (PDV) (32% RR).
B io logic therapy: There is evidence that the immune system can influ­
en ce  the pathogenesis of melanoma. Several biologic agents have been 
tested in patients with metastatic melanoma and have demonstrated anti­
tum or activity. Interferon a (16% RR) and Interleukine 2 (18% RR).
C om binations of biologic agents and chemotherapy: Exploration 
of combinations of biological agents and chemotherapy for treatment of 
m elanom a Is an active area of investigation. Preclinical studies on animals 
h ave  suggested that combinations of recombinant cytokines or monoclonal 
antibodies (e.g. IL2 and Interferon a, monoclonal antibody and IL2, tumor 
necrosis factor and Interferon y) are additive or synergistic. Clinical tri­
als of cytokines with chemotherapy have been initiated and have shown 
promising results (45-50% RR) with some 5 to 10% long term unmalntained 
remissions.
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T cell recognition of melanoma-derived antigens: Implication 
fo r peptide based immunotherapy
L. RiVoitinL A. Mazzocchi, P. Squarcina, F. Arienti, F. Belli, C, Castelli,
F .M . Martncola, D.J. Loftus, G. Parmlani. National Tumor Institute of 
Mi/anOj Italy and National Cancer Institute, NIHt Bethesda MD, USA
A  high number of T cell-recognized epitopes expressed on melanoma cells 
h a s  been recently identified. However, it is still unclear which antigen could 
b e  effective in mediating a significant anti-tumor response when used as 
a  vaccine. Preliminary studies showed that immunization of melanoma 
patients with epitopes derived from proteins of the MAGE family (whose 
system ic immunogenicity, i.e. the ability of inducing specific CTL in periph­
era l blood of melanoma patients after in vitro culture, is apparently low) may 
result in significant clinical responses. On the other hand, no major tumor 
regression could be observed when patients were vaccinated with epitopes 
derived  from the differentiation antigen MART-1 /Melan A, an antigen that 
h as  been shown to be the most immunogenic in HLA-A2.1 melanoma 
patients. It is thus crucial to identify the mechanisms responsible for the 
fa ilu re  of some antigens to mediate a significant anti-tumor response in 
vivo. One of these mechanisms has been recently identified as related to 
th e  existence of natural analogs of the MART-1 immodominant epitope in 
norm al human proteins other than MART-1. These analogs exert a partial 
agonist/antagonist activity on MART-1-specific CTL, thus possibly playing 
a  role in down modulating in vivo anti-melanoma CTL reactivities.
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O n the molecular genetics of malignant melanoma
U . Rlnoboro. A. Platz, J. Hansson, Department of Oncology, 
Ftadiumhemmet, Karoiinska Hospital, Stockholm, Sweden
C utaneous malignant melanoma in its hereditary form is involved in 6-10%  
of all melanoma cases. Genetic linkage analyses have revealed loci on 
chrom osom es 1 and 9 as probable locations for genes responsible for the 
hereditary increased risk of malignant melanoma. Important steps forward 
w e re  the localization of the CDKN2A gene to chromosome 9p21 and 
Ih e  obtained evidence of its involvement in the etiology of melanoma. 
C D K N 2 A  germline mutations in American melanoma prone families have 
b e e n  linked to the development of the disease. In a large series of Swedish 
m elanom a families the mutated gene was found in about 10% of the 
kindres. The CDKN2A gene product p16 has a regulatory effect on the
cell cycle by interacting with cyclin dependent kinases. The product of a 
second gene, CDKN2B, on chromosome 9p21> has a similar function but 
no germline mutations have been observed. Both CDKN2A and CDKN2B 
mutations have, however, been observed in sporadic melanoma tumors. 
Other genes involved In the regulation of the cell cycle are at present 
studied. A germline mutation in the CDK4 gene have been registered in 
two American melanoma families. Molecular genetic studies of sporadic 
melanoma point at several cell cycle regulation control genes as possible 
targets for inherited DNA alterations predisposing for melanoma. Whether 
additional genes with functions in other pathways are involved in melanoma 
genetics remains to be determined.
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Regional therapy for melanoma: Randomised trials
F. Lejeune, H. Schraffordt Koops, B. Kroon, A. Eggermont. University 
Hospitals of Lausanne Groningen, Amsterdam, Rotterdam, Netherlands
A phase til study-EORTC 18832 and WHO Melanoma CT n°15 -  on 
the value of prophylactic Isolated Limb Perfusion with melphalan (M-ILP) 
for >1.5 mm melanoma entered 832 evaluable (ev) pts from 17 centers. 
Median follow up is 6,4 years. There was a trend for longer DFI after ILP. 
The difference is significant if the pts with no ELND are separately analysed, 
with a high significance in the 1.5-3 mm thickness subgroup. The impact 
of ILP was clearly on the occurrence of in transit metastases (ITM) which 
were reduced from 6.6% to 2.2%. There was no benefit of ILP in terms of 
survival.
In advanced melanoma of the limbs, ILP with melphalan combined with 
rTNFa and IFNy (TEM-LP) gives 100% objective responses in in-transit 
melanoma mets. A prospective randomized phase II study compared 32 
pts who received TIM-ILP to 32 pts who received TM-ILP (without lFNy;r). 
There was an ORR and CR rate superior with TIM over TM *100% vs 91% 
and 78% vs 69% respectively-, but the differences are not significant.
Conclusion: Prophylactic M-ILP cannot be recommended as as a stan­
dard adjunct to surgery in high risk primary limb melanoma. TIM-ILP or 
TM-ILP is a regional therapy with very high regional response rate on 
melanoma in-transtt mets.
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Targeted immunotherapy: Dendritic cells to present 
tumor-associated antigens
Carl G. Figdor, Department of Tumor immunology, University Hospital 
Nijmegen, Philips van Leydenlaan 25, 6525 EX Nijmegen, The Netherlands
Dendritic cells (DC) are thought key regulators In immune responses, (n 
particular DC, because of their efficient antigen uptake and processing ma­
chinery and their high expression of MHC class I and class II molecules, are 
well equipped to stimulate naive lymphocytes. Until recently, the extremely 
low abundance of DC in the circulation has hampered the study of these 
antigen presenting cells. Recently, several studies have demonstrated that 
It is possible to obtain DC from bone marrow or from peripheral blood 
monocytes after in vitro culture with cytokines. In particular GM-CSF and 
IL4 are frequently used. These immature DC can be further differentiated 
into mature DC using cytokines like TNF or iL-1. These cells express high 
levels of MHC molecules, and also CD80, CD83, and CD86. We and oth­
ers were capable, using these DC as antigen presenting cells, to induce 
primary immune responses against melanocyte differentiation antigens. 
Thus we obtained several CTL from blood of healthy donors as well as 
from melanoma patients that recognize melanocyte differentiation antigens. 
These findings demonstrate that DC may be powerful Immunogens and 
several strategies to use DC to treat cancer patients have recently been 
developed. These not only include the injection of DC loaded with peptides 
or proteins derived from tumor associated antigens, but also DC transduced 
with RNA or DNA encoding such proteins may be considered.
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Surgery: Still the gold standard?
T. Lerut. W. Coosemans, P. De Leyn, G. Deneffe, D. Van Raemdonck. 
Department of Thoracic Surgery, University Hospital Leuven, Belgium
Surgery as primary treatment for cancer of the oesophagus and gastro- 
oesophageal junction today is challenged by a variety of multi-modality 
regimens. Several groups, including our own, however have continued to 
advocate radical resection and extended lymphadenectomy as the primary
